辉瑞 CEO 否认会允许在中国生产 Paxlovid 仿制版药，称其不是穷国

来源: 三河匹夫 于 2023-01-10 16:23:14 [] [旧帖] [给我悄悄话] 阅读数 : (16943 bytes)
本帖于 2023-01-10 16:24:33 时间, 由普通用户 三河匹夫 编辑
 
Vandana Singh
·1 min read
 
 
In this article:
  • Albert Bourla
    Greek-American pharmaceutical executive
 
 

  • Pfizer Inc (NYSE: PFE) CEO Albert Bourla rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid.

  • Bourla speaking at JPMorgan's healthcare conference, said, "We are not in discussions. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market."

  • Related: New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows.

  • Bourla said the company shipped thousands of Paxlovid courses in 2022 to China and, in the past couple of weeks, had increased that to millions.

  • Concurrently, China's Healthcare Security Administration (NHSA) declined to include Paxlovid in a national reimbursement list that would have allowed patients to get it at a lower price throughout the country.

  • Bourla added, "So they want it lower than the lowest of the middle, and we didn't agree. They are the second-highest economy in the world. And I don't think that they should pay less than Salvador, right, which is a poor country"..."We will continue with the private market in China, which is significant."

  • Price Action: PFE shares are up 0.10% at $48.44 during the premarket session on the last check Tuesday.

请您先登陆，再发跟帖！